• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Kindred Biosciences, Inc.

    8/27/21 5:07:54 PM ET
    $KIN
    Major Pharmaceuticals
    Health Care
    Get the next $KIN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-36225
    Issuer: Kindred Biosciences, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 1499 Bayshore Highway
    Suite 226
    Burlingame CALIFORNIA 94010
    Telephone number: 415-596-1557
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-08-27 By Tara Petta Director
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KIN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kindred Biosciences downgraded by Lake Street with a new price target

      Lake Street downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $12.00 previously

      6/17/21 11:33:29 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Kindred Biosciences from Buy to Neutral and set a new price target of $9.25 from $9.00 previously

      6/17/21 6:07:16 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • Kindred Biosciences downgraded by Aegis Capital with a new price target

      Aegis Capital downgraded Kindred Biosciences from Buy to Hold and set a new price target of $9.25 from $16.00 previously

      6/16/21 9:21:39 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • Elanco Announces Agreement to Acquire Kindred Biosciences

      Bolt-on Acquisition Accelerates Elanco's Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time    Elanco will acquire all outstanding stock of Kindred Biosciences at a price of $9.25 per share, or approximately $440 million, a premium of 52% based on the 30-day average. Transaction brings three potential blockbusters in the development phase, complements existing pipeline, and augments monoclonal antibody R&D capabilities. Increasing Investor Day revenue from innovation expectation by $100 million, to $600 million to $700 million by 2025, with significant opportunity beyond the period. Differentiated, disruptive portfolio in ato

      6/16/21 6:30:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

      SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group. KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE:ELAN). In this randomized, blinded, placebo-controlled study, KIND

      6/2/21 8:31:00 AM ET
      $KIN
      $ELAN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $KIN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Kindred Biosciences, Inc.

      15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/7/21 6:09:47 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kindred Biosciences, Inc.

      EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)

      9/2/21 12:15:28 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Kindred Biosciences, Inc.

      S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)

      8/30/21 9:21:56 AM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      9/13/21 4:30:56 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/31/21 4:00:27 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)

      SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)

      8/5/21 4:24:14 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care

    $KIN
    Leadership Updates

    Live Leadership Updates

    See more
    • TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po

      10/24/22 9:00:00 AM ET
      $ELAN
      $PRTS
      $TSPQ
      $KIN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Auto & Home Supply Stores
      Consumer Discretionary
    • TCW Special Purpose Acquisition Corp. Announces Appointment of Nanxi Liu to Advisory Board

      TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to its Advisory Board, effective April 26, 2021. Ms. Liu is Co-Founder and CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics. Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of aut

      4/26/21 8:30:00 AM ET
      $PRTS
      $KIN
      Auto & Home Supply Stores
      Consumer Discretionary
      Major Pharmaceuticals
      Health Care

    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Park West Asset Management Llc

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      9/13/21 4:30:38 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 9:46:23 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company

      4 - Kindred Biosciences, Inc. (0001561743) (Issuer)

      8/30/21 6:08:02 PM ET
      $KIN
      Major Pharmaceuticals
      Health Care